BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
BC Week In Review | Feb 22, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Feb. 20, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic...
BC Extra | Feb 21, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Wednesday, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic esophagitis....
BioCentury | May 27, 2013
Emerging Company Profile

Calypso: Fistula fix

Calypso Biotech S.A. has mAbs against an undisclosed target to treat fistulizing Crohn's disease, a severe form of the condition that usually is refractory to marketed therapies such as immunomodulators. The company expects it will...
BC Week In Review | May 20, 2013
Company News

Calypso Biotech, iDD Biotech deal

iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002 , a humanized mAb, to treat refractory celiac disease. iDD received an upfront payment and is eligible for milestones, plus royalties. CALY-002 is in preclinical development, and...
Items per page:
1 - 5 of 5